CD274 and neoplasm: These immunomodulatory actions of RSV in the tumor microenvironment, together with its ability to interfere with the glycosylation-driven stability of the immune checkpoint PD-L1, provides experimental evidence in support of combining RSV, which is virtually nontoxic with respect to its systemic effects, with immune checkpoint inhibitors, and might form the basis of future clinical trials.